News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
203 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37190)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53929)
2023 (42568)
2024 (38488)
2025 (26337)
Month
January (4681)
February (5218)
March (5801)
April (5233)
May (5822)
June (5224)
July (4072)
August (4645)
September (4519)
October (4153)
November (5533)
December (3823)
Day
1 (258)
2 (248)
3 (119)
4 (1)
5 (30)
6 (211)
7 (196)
8 (187)
9 (224)
10 (123)
11 (42)
12 (30)
13 (282)
14 (254)
15 (234)
16 (227)
17 (162)
18 (1)
19 (7)
20 (203)
21 (157)
22 (183)
23 (103)
24 (13)
25 (1)
27 (71)
28 (66)
29 (85)
30 (85)
31 (20)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
27
28
29
30
31
Drug Development
Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for EDIT-301 for the treatment of transfusion-dependent beta thalassemia (TDT), enabling the Company to initiate a Phase 1/2 clinical study of EDIT-301 in TDT patients.
December 20, 2021
·
5 min read
Pharm Country
Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection
Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted Transitional Drug Add-On Payment Adjustment (TDAPA) to KORSUVA™ (difelikefalin) injection in the anti-pruritic functional category.
December 20, 2021
·
7 min read
Drug Development
MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and Rapid Debridement in Chronic and Hard to Heal Wounds
MediWound Ltd. (Nasdaq: MDWD) (the “Company”), today announced positive initial data from seven of the maximum fifteen patients in its ongoing open-label, phase 2 pharmacology study of EscharEx®, the company’s next-generation enzymatic debridement agent under development for chronic and hard-to-heal wounds.
December 20, 2021
·
8 min read
Pharm Country
CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
CytoSorbents Corporation announces the publication of results from the Company’s U.S. CytoSorb Therapy in COVID-19 (CTC) retrospective registry in the peer-reviewed journal, Frontiers in Medicine.
December 20, 2021
·
8 min read
Business
Tilray to Announce Second Quarter Fiscal 2022 Financial Results on January 10, 2022Company to Also Host Fireside Chat at the 24th Annual ICR Conference on January 10, 2022
Tilray, Inc. (“Tilray” or the “Company”) (NASDAQ: TLRY; TSX: TLRY) announced that the Company will release financial results for its second quarter fiscal 2022 ended November 30, 2021 before financial markets open on January 10, 2022.
December 20, 2021
·
2 min read
InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma
InMed Pharmaceuticals Inc. today announced that a peer-reviewed scientific article entitled “ Cannabinol Modulates Neuroprotection and Intraocular Pressure has been published.
December 20, 2021
·
6 min read
Business
Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu® (carglumic acid)
Eton Pharmaceuticals, Inc and ANI Pharmaceuticals, Inc (Nasdaq: ANIP), a bio-pharmaceutical company serving patients in need through the development and manufacturing of high-quality generic and branded medicines, today announced the commercial launch of Carglumic Acid tablets.
December 20, 2021
·
7 min read
BioMidwest
Clarametyx Biosciences Awarded $3.15 Million Grant From NIH to Advance a Broad-Spectrum Vaccine Technology for Bacterial Infections
Clarametyx Biosciences Inc. today announced the receipt of a grant from the National Institute on Deafness and Other Communication Disorders (NIDCD) at the National Institutes of Health (NIH) for up to $3.15 million over three years.
December 20, 2021
·
3 min read
Biotech Beach
CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of CG0070 in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
CG Oncology, Inc. announced today it has triggered the first development milestone payment under its licensing agreement with Kissei Pharmaceutical Co., Ltd. for its oncology immunotherapy CG0070 for Japan South Korea, Taiwan and other Asian countries with the exception of China.
December 20, 2021
·
2 min read
ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope® TATX-03 Antibody Cocktail Manufacturing Collaboration
ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope ® TATX-03 Antibody Cocktail Manufacturing Collaboration.
December 20, 2021
·
6 min read
Previous
9 of 21
Next